Cargando…

Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis

OBJECTIVES: To examine the performance of the urinary biomarker panel tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients with sepsis at ICU admission. To investigate the effect of nonrenal organ dysfunction on tissue inhibitor of metalloproteinase-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Honore, Patrick M., Nguyen, H. Bryant, Gong, Michelle, Chawla, Lakhmir S., Bagshaw, Sean M., Artigas, Antonio, Shi, Jing, Joannes-Boyau, Olivier, Vincent, Jean-Louis, Kellum, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089124/
https://www.ncbi.nlm.nih.gov/pubmed/27355527
http://dx.doi.org/10.1097/CCM.0000000000001827
_version_ 1782464220176056320
author Honore, Patrick M.
Nguyen, H. Bryant
Gong, Michelle
Chawla, Lakhmir S.
Bagshaw, Sean M.
Artigas, Antonio
Shi, Jing
Joannes-Boyau, Olivier
Vincent, Jean-Louis
Kellum, John A.
author_facet Honore, Patrick M.
Nguyen, H. Bryant
Gong, Michelle
Chawla, Lakhmir S.
Bagshaw, Sean M.
Artigas, Antonio
Shi, Jing
Joannes-Boyau, Olivier
Vincent, Jean-Louis
Kellum, John A.
author_sort Honore, Patrick M.
collection PubMed
description OBJECTIVES: To examine the performance of the urinary biomarker panel tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients with sepsis at ICU admission. To investigate the effect of nonrenal organ dysfunction on tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this population. METHOD: In this ancillary analysis, we included patients with sepsis who were enrolled in either of two trials including 39 ICUs across Europe and North America. The primary endpoint was moderate-severe acute kidney injury (equivalent to Kidney Disease Improving Global Outcome stage 2–3) within 12 hours of enrollment. We assessed biomarker performance by calculating the area under the receiver operating characteristic curve, sensitivity, specificity, and negative and positive predictive values at three cutoffs: 0.3, 1.0, and 2.0 (ng/mL)(2)/1,000. We also calculated nonrenal Sequential Organ Failure Assessment scores for each patient on enrollment and compared tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in patients with and without acute kidney injury and across nonrenal Sequential Organ Failure Assessment scores. Finally, we constructed a clinical model for acute kidney injury in this population and compared the performance of the model with and without tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7. RESULTS: We included 232 patients in the analysis and 40 (17%) developed acute kidney injury. We observed significantly higher urine tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients with acute kidney injury than without acute kidney injury in both patients with low and high nonrenal Sequential Organ Failure Assessment scores (p < 0.001). The area under the receiver operating characteristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0.73–0.92) and 0.85 (0.76–0.94), in low and high nonrenal Sequential Organ Failure Assessment score subgroups. Performance of the tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was not modified by nonrenal Sequential Organ Failure Assessment (p = 0.70). In multivariate analysis, the addition of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significantly improved the performance of a clinical model for predicting acute kidney injury (p = 0.015). CONCLUSION: Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately predicts acute kidney injury in septic patients with or without other organ failures.
format Online
Article
Text
id pubmed-5089124
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-50891242016-11-07 Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis Honore, Patrick M. Nguyen, H. Bryant Gong, Michelle Chawla, Lakhmir S. Bagshaw, Sean M. Artigas, Antonio Shi, Jing Joannes-Boyau, Olivier Vincent, Jean-Louis Kellum, John A. Crit Care Med Clinical Investigations OBJECTIVES: To examine the performance of the urinary biomarker panel tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients with sepsis at ICU admission. To investigate the effect of nonrenal organ dysfunction on tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this population. METHOD: In this ancillary analysis, we included patients with sepsis who were enrolled in either of two trials including 39 ICUs across Europe and North America. The primary endpoint was moderate-severe acute kidney injury (equivalent to Kidney Disease Improving Global Outcome stage 2–3) within 12 hours of enrollment. We assessed biomarker performance by calculating the area under the receiver operating characteristic curve, sensitivity, specificity, and negative and positive predictive values at three cutoffs: 0.3, 1.0, and 2.0 (ng/mL)(2)/1,000. We also calculated nonrenal Sequential Organ Failure Assessment scores for each patient on enrollment and compared tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in patients with and without acute kidney injury and across nonrenal Sequential Organ Failure Assessment scores. Finally, we constructed a clinical model for acute kidney injury in this population and compared the performance of the model with and without tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7. RESULTS: We included 232 patients in the analysis and 40 (17%) developed acute kidney injury. We observed significantly higher urine tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients with acute kidney injury than without acute kidney injury in both patients with low and high nonrenal Sequential Organ Failure Assessment scores (p < 0.001). The area under the receiver operating characteristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0.73–0.92) and 0.85 (0.76–0.94), in low and high nonrenal Sequential Organ Failure Assessment score subgroups. Performance of the tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was not modified by nonrenal Sequential Organ Failure Assessment (p = 0.70). In multivariate analysis, the addition of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significantly improved the performance of a clinical model for predicting acute kidney injury (p = 0.015). CONCLUSION: Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately predicts acute kidney injury in septic patients with or without other organ failures. Lippincott Williams & Wilkins 2016-10 2016-09-16 /pmc/articles/PMC5089124/ /pubmed/27355527 http://dx.doi.org/10.1097/CCM.0000000000001827 Text en Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Clinical Investigations
Honore, Patrick M.
Nguyen, H. Bryant
Gong, Michelle
Chawla, Lakhmir S.
Bagshaw, Sean M.
Artigas, Antonio
Shi, Jing
Joannes-Boyau, Olivier
Vincent, Jean-Louis
Kellum, John A.
Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title_full Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title_fullStr Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title_full_unstemmed Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title_short Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for Risk Stratification of Acute Kidney Injury in Patients With Sepsis
title_sort urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 for risk stratification of acute kidney injury in patients with sepsis
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089124/
https://www.ncbi.nlm.nih.gov/pubmed/27355527
http://dx.doi.org/10.1097/CCM.0000000000001827
work_keys_str_mv AT honorepatrickm urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT nguyenhbryant urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT gongmichelle urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT chawlalakhmirs urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT bagshawseanm urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT artigasantonio urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT shijing urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT joannesboyauolivier urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT vincentjeanlouis urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis
AT kellumjohna urinarytissueinhibitorofmetalloproteinase2andinsulinlikegrowthfactorbindingprotein7forriskstratificationofacutekidneyinjuryinpatientswithsepsis